Limited healthcare budgets demand smart investments. Low- and middle-income countries battle HIV/AIDS, malaria, syphilis, and tuberculosis. A recent study ranks cost-effective interventions. It uses incremental cost-effectiveness ratios (ICERs) to measure cost per disability-adjusted life-year (DALY) averted. The analysis predicts ICERs for 14 interventions across 128 countries. It factors in GDP per capita and disease burden. Country-specific league tables guide funding priorities. Here are the key findings.

Key Insights

Most Cost-Effective Interventions

• Antenatal Syphilis Screening: Tops the list in 81 countries. Median ICER ranges from $3 in Equatorial Guinea to $3473 in Ukraine. It prevents congenital syphilis at low cost.
• Chemotherapy for Drug-Susceptible TB: Leads in 23 countries, second in 59. Median ICER is $46, reflecting high efficacy and low costs.
• Malaria Prevention (Pregnant Women): Excels in Nigeria and beyond. Low ICERs stem from high burden and affordable treatment.
• Malaria Prevention (Infants): Matches pregnant women’s treatment. It shines in high-burden areas like Sudan.
• Option B+ (Lifelong ART for Pregnant Women): Ranks third in 15 countries. Median ICER ranges from $81 in Somalia to $2296 in Maldives. It curbs mother-to-child HIV transmission.

Least Cost-Effective Interventions

• PrEP for Men Who Have Sex with Men: Highest ICER in 116 countries, from $2326 in Lesotho to $53559 in Maldives. High drug costs limit value.
• PrEP for Heterosexuals Aged 10+: Second highest in 115 countries. Median ICER spans $1729 in Lesotho to $43765 in North Macedonia.
• ART for Prevention (Aged 0-9): High ICERs, like in Sudan, due to low disease burden and costly treatment.
• ART for Prevention (Aged 10+): Often exceeds thresholds, as in India, due to long-term costs.
• Xpert TB Test: Costly in places like Nigeria. It has less impact on DALYs than treatments.

Conclusion

This study shapes smarter health investments. Antenatal syphilis screening and TB chemotherapy deliver big results affordably. PrEP, though vital, needs targeted use due to high costs. Country-specific tables align funding with local needs. Decision-makers can boost health outcomes despite tight budgets. This approach drives efficiency and equity.